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Introduction
Breast cancer is the most common cancer among women (ASR-43.1) with highest mortality rates (Ferlay J) . Breast cancer is broadly classified into non-invasive ductal carcinoma in situ (DCIS) and invasive-ductal carcinoma (IDC) . Understanding the mechanism of breast carcinogenesis at genetic and transcriptional level can aid in characterization of DCIS or early stage IDC tumors. Gene expression signatures are used to classify IDC subtypes of hormone receptor positive (estrogen and progesterone receptors) i.e., luminal A & B and hormone receptor negative-HER2 & basal like (Perou et al., 2000; Sorlie et al., 2001 ) breast cancer subtypes. Next generation sequencing has enabled global profiling of mRNAs and non-coding RNAs (ncRNAs) including long non-coding RNAs (lncRNAs) and microRNAs.
LncRNAs have gained immense importance in gene regulation and are known to play an important role in cancer development and prognosis (Huarte, 2015; Prensner and Chinnaiyan, 2011; Rao et al., 2017) . Understanding the divergent expression of lncRNAs in early stage breast tumors can help elucidate its functional role in carcinogenesis.
Specific lncRNA signatures are known to be associated with different molecular subtypes of breast cancer. DSCAM-AS1 was identified specifically in ER positive breast tumors and shown to increase aggression and drug resistance (Niknafs et al., 2016) . Similarly, AFAP1-AS1 was predominantly found to be dysregulated in HER2 and triple negative breast cancers (TNBC) (Shen et al., 2015; Yang et al., 2016a) . H19 was identified to be over-expressed in ER/PR positive breast adenomas and BC200 was implicated to be distinctly elevated in benign tumors and not in invasive subtypes and hence are of prognostic significance (Adriaenssens et al., 1998; Iacoangeli et al., 2004) . HOTAIR was demonstrated to gain activity in BRCA1 mutated tumors. In a normal cell, BRCA1 competes with HOTAIR in binding to EZH2 of PRC2 (Wang et al., 2013) . The functional characteristics of certain lncRNAs like UCA1, GAS5 and XIST, have established them as breast cancer associated tumor suppressors while HOTAIR, TINCR and DSCAM-AS1 are known as oncogenic lncRNAs Xu et al., 2017) .Support vector machine-based prediction of breast cancer intrinsic subtype using lncRNA expression profile and PAM50 gene signature using TCGA datasets was recently proposed as an improved prediction model .
Despite known association of lncRNA expression with molecular subtype, recently reported lncRNAs have emerging role in relevant signaling or druggable pathways. LncRNA CYTOR was reported to be associated with breast cancer progression through EGFR signaling pathway (Van Grembergen et al., 2016) . NKILA was observed to promote heterotrimeric complex formation (p50/p60/IκB) and inhibit IκB phosphorylation, thus regulating NFκB signaling . LINK-A was reported to aid in stabilizing HIF1α in normoxic conditions of TNBC. Through BRK/PTK6 activation and phosphorylation of HIF1α, LINK-A substantiates its kinase activation and cancer signaling potential (Lin et al., 2016) .
Alternatively, breast cancer associated lncRNAs important in drug targeting pathways can also be useful prognostic biomarkers. In the present study, we have done RNA sequencing in early stage tumors (stage I-IIA IDC, DCIS) and non-cancerous breast tissue samples to identify lncRNAs that play a role in early stage breast cancer. We speculate that aberrant expression of lncRNAs could be an early event in breast cancer development and hence the study was aimed to identify dysregulated lncRNAs, and the mechanism of dysregulation in breast cancer.
Materials and methods

Study population and sample classification
The study cohort includes patients diagnosed and treated for breast cancer at Cancer Institute (WIA), Chennai, Tamil Nadu, India. These patients were histologically confirmed of infiltrating ductal carcinoma (IDC -Stage I-II A) and ductal carcinoma in situ (DCIS).
Apparently normal breast tissues were obtained from patients undergoing surgery for breast conditions other than malignancy. Samples having >70% for cancer cells following histopathological examination were included in the study. Paired normal and apparently normal tissues completely free of tumor cells were selected and kept frozen (-80ºC) until further processing. Total RNA sequencing was done for 24 samples i.e. tumor (n=6), paired normal (matched normal; n=6), DCIS (n=7), and apparently normal (n=5). Validation cohort of IDC (n=52) and corresponding paired normal tissue were used to gauge candidate lncRNAs. The clinico-pathological features of patients in the discovery and validation cohort are detailed in Supplementary Table S1 . All patients were informed about the study and their written consent for participation was obtained. The Institutional Ethical Committee approved the study and the protocol.
RNA isolation and library preparation
Total RNA was isolated from frozen tissues using TRIZOL method and purification by Nucleospin RNA isolation kit (Machery-Nagel, GmbH), which includes an on-column DNase treatment. The quality and quantity of total RNA was evaluated through Bioanalyzer 2100 (Agilent Technologies, CA, USA). Ribosomal RNA was depleted (Epigentek, USA) and cDNA library was prepared using Illumina TruSeq Stranded Total RNA Library Prep Kit.The library profile was verified using 2100 Bioanalyzer (Agilent Technologies, CA, USA).
Subsequent RNA sequencing of cDNA libraries with paired-end reads (2 x 100 bps reads) were performed according to the standard Illumina protocol using HiSeq2500 sequencing platform.
RNA sequencing and data analysis
Raw reads were assessed for Phred quality using FastQC (Andrews); and low bases and adaptor sequences were trimmed off using Fqtrim (Pertea, 2015) retaining reads of length ≥ 75 bases. Clean reads were aligned against human reference genome (GRCh38 assembly) with Gencode V24 annotation using Hisat2 (Baruzzo et al., 2017) with default parameters.
Exon centric read counts were obtained from binary alignment map (BAM) using HTSeq (Anders et al., 2015) using the script 'htseq count' for all samples independently.
LncRNAs identified with
≥ 15 reads in at least 3 samples per cohort i.e. IDC, paired normal, DCIS and apparent normal were further investigated for differential expression using DESeq (Anders and Huber, 2010) . Read counts obtained from HTSeq were normalized using 'estimateSizeFactors' variance and were modeled using 'estimateDispersions'. The differentially expressed genes were computed using 'nbinomTest' functions of DEseq.
Significant differential expression was defined if |log 2 (fold-change)| > 1 and q-value (BH adjusted P value) < 0.1. Expression profile of long non-coding RNA from TCGA breast cancer dataset (TCGA-BRCA; n=837 invasive tumors and n=105 normal samples) was used for survival analysis . Kaplan-Meier plots for differentially expressed lncRNAs were generated for tumor stages as well as molecular subtypes and evaluated using log rank test.
LncRNA-mRNA co-expression network analysis
Pearson's correlation coefficient (PCC) was used to determine linear correlation between mRNA and lncRNA expression profiles using R. Differentially expressed lncRNA-mRNA pairs with |PCC| ≥ 0.9 were considered for network analysis using STRING v10 (Szklarczyk et al., 2015) with organism "Human" as backend database and Cytoscape (Shannon et al., 2003) .
Real-time quantitative PCR
Total RNA of 500 ng was used for preparing cDNA libraries using QuantiTect Reverse 
Statistical analyses
GraphPad Prism (Version 7.0, La Jolla, California, USA) was used for evaluating qRT-PCR gene expression data. Student's t-test was used for pair-wise analysis of tumor and paired normal samples. Welch correction was done if significant difference in variance was observed and Wilcoxon rank sum test was applied whenever non-Gaussian distribution was followed. In agreement with previous reports, lncRNAs were expressed at comparatively lower levels than mRNAs [Supplementary Figure We observed antisense RNAs (asRNA) and long intergenic RNAs (lincRNAs) to be the major lncRNA subtypes differentially expressed among these four groups. Antisense RNAs accounted for 58.9% of total differentially expressed lncRNAs in IDC compared to paired normal and 55.3% compared to apparently normal samples.
Results
Expression profile of lncRNAs in ductal carcinoma in situ and invasive ductal carcinoma
[ Figure 1 E-F]. WDR86-AS1, emerged as a novel antisense lncRNA in our data whereas ADAMTS9-AS2 (Li et al., 2017; Peng et al., 2017) and ST8SIA6-AS1 (Yang et al., 2016a; Yang et al., 2016b) Further, LINC01614, RP11-490M8.1 and CTB-92J24.3 were novel DElncRNAs identified in early staged breast cancer.
Identification of novel lncRNAs differentially expressed in breast tumors
Validation of candidate lncRNA expression in breast tumor and paired normal
We selected 12 candidate lncRNAs (5 Upregulated lncRNAs: MIAT, FAM83H-AS1, LINC01614, ST8SIA6-AS1, CTB-131K11.1 and 7 down regulated lncRNAs: ADAMTS9-AS2, EPB41L4A-AS1, WDFY3-AS2, RP11-161M6.2, RP11-295M3.4, RP11-490M8.1, CTB-92J24.3) for validation using TaqMan™ gene expression assays in n=52 early staged IDC samples [ Figure 3A ]. We observed statistically significant dysregulation of seven out of twelve lncRNAs identified using RNA-Seq. Among them ADAMTS9-AS2 [ Figure 3B ] was observed to be the most commonly down regulated lncRNA in tumor tissues (13.59 folds).
We also confirmed significant down regulation of CTB92J24.3(11.82 folds), RP11-295M3.4
(3.5 folds), RP11-490M8.1 (3.7 folds), WDFY3-AS2 (4.3 folds) and EPB41L4A-AS1 (2.09 folds) [ Figure 3C -G]. FAM83H-AS1 was most significantly overexpressed lncRNA in tumors (8.9 folds) compared to the paired normal tissues [ Figure 3H ]. Although, MIAT and LINC01614 were upregulated, statistically were insignificant [ Figure 
ADAMTS9-AS2 promoter is hyper-methylated in breast tumors
Yao et al reported the downregulation of ADAMTS9-AS2 by promoter methylation in gliomas . Hence methylation levels of the promoter region of ADAMTS9-AS2 in our validation set of tumor and paired normal samples (n= 52) was done using pyrosequencing. We observed a nearly two folds (1.9) increase in methylation levels (p< 0.0001) in the promoter region (+879 to +929 bp from TSS) of tumor samples compared to paired normal samples [ Figure 4A ].
Knock-down of DNA methyltransferase 1 increases ADAMTS9-AS2 expression
In order to investigate promoter methylation mediated regulation of ADAMTS9-AS2 expression, DNMT1 was knocked down in MDAMB-231 and MCF7 using short interfering RNA. The down regulation of DNMT1 led to subsequent over expression of ADAMTS9-AS2 by 1.93-fold (p<0.001) and 2.32-fold (p<0.001) in MDAMB-231 and MCF7
respectively [ Figure 4B -C]. Loss of promoter methylation was observed using pyrosequencing in DNMT1 siRNA transfected MDAMB-231 (2.6 folds; p=0.001) and MCF-7 cells (6.7 folds; p=0.007) [Figure 4 D] . These results show that ADAMTS9-AS2 is over expressed in both MDAMB-231 and MCF7 cells following DNMT1 silencing indicating methylation-mediated suppression of ADAMTS9-AS2 in breast cancer cells.
Prognostic lncRNAs in early stage breast cancer
Survival analysis was done to investigate the prognostic potential of candidate lncRNA using TCGA datasets. We observed FAM83H-AS1 was significantly overexpressed by ~4 fold in TN, TA as well as DA pairs and its overexpression is associated with overall poor survival in Figure 5K ]. We observed significant association with overexpression of WDFY3-AS2 [ Figure 5G ] and down regulation of RP11-161M6.2 in stage2 of breast cancer based on TANRIC analysis indicating them as potential early prognostic markers [ Figure 5G and J].
Co-expression and pathway analysis
Guilt-by-association method was employed to speculate the putative functions of lncRNAs.
This approach investigates the association of mRNA expression patterns with lncRNAs using Co-expressed mRNAs were further analyzed using StringDB for network analysis. To augment guilt by association concept, we further focused on mRNA network that are reported to co-express irrespective of lncRNA. We observe that partial sets of mRNAs from 22
DElnRNAs in IDC compared to paired normal samples were co-expressed according to Cytoscape, we were able to segregate the sub network of 76 genes potentially governed jointly by TINCR (65 genes) and LINC01359 (55 genes), which resulted in sub modules of genes with core histone protein domains (green nodes) and involved in pathways in cancer (blue nodes).
Discussion
Aberrant expression of long non-coding RNAs (lncRNAs) is documented in various cancers (Huarte, 2015; Prensner and Chinnaiyan, 2011) . In recent years, lncRNAs have gained importance in early detection and better prognosis of tumors (Chandra Gupta and Nandan Tripathi, 2017). Although several lncRNAs associated with breast cancer have been reported previously, studying aberrantly expressed lncRNAs specific to early stage breast cancer will provide insight into molecular mechanisms associated with breast cancer development. It will also result in identification of putative markers that might be useful in diagnosis or prognosis of breast cancer. Previous studies have associated altered expression of lncRNAs with specific breast cancer subtypes. For example, HOTAIR is a lncRNA that is highly expressed in HER2+ breast cancers whereas HOTAIRM1 is highly expressed in basal-like subgroup of breast cancers (Su et al., 2014) . LuminalA types showed over expression of LINC00160 and abundance of DSCAM-AS1 was reported in luminalB subtypes of breast cancer (Jonsson et al., 2015; Vu et al., 2016) . MALAT, lncRNA-ATB, BC200, XIST, H19
are some of other lncRNAs frequently associated with breast tumorigenesis and progression (Hansji et al., 2014) . 92J24.3 and significant over expression of FAM83H-AS1 in breast cancer. We found ADAMTS9-AS2 to be significantly down regulated in tumor compared to paired normal breast tissues. ADAMTS9-AS2, is an antisense transcript originating from the opposite stand coding for ADAMTS9 which is a known inhibitor of angiogenesis and is implicated to have a tumor suppressive role. Functional importance of ADAMTS9 in nasopharyngeal and esophageal cancers has been described (Lo et al., 2010) . ADAMTS9-AS2 like ADAMTS9 is down regulated in glioblastoma , colorectal cancer , bladder cancer, lung adenocarcinoma and ER+ breast cancers (Li et al., 2017 (Richards et al., 2016) . Down regulation of WDFY-AS2 was found in diffuse glioma and strongly associated with poor prognosis (Wu et al., 2018) . EPB41L4A-AS1 (also known as TIGA1) has been shown to be transcribed during growth arrest but has not been extensively studied in cancer to elucidate its role (Yabuta et al., 2006) . RP11-161
M6.2 was found to be over expressed in ER/PR negative and HER2 positive breast cancers in our samples. The finding indicates an association of RP11-161 M6.2 and estrogen receptor and is possibly down regulated in estrogen mediated signaling. Similarly, MIAT was dominantly expressed in ER/PR/HER2+ breast cancers samples.
FAM83H-AS1 was consistently over expressed in breast tumor samples and overall survival analysis of TCGA data sets showed poor prognosis of the up regulated group which are in agreement with other studies in breast, colorectal and lung cancer (Lu et al., 2018; Yang et al., 2016a; Yang et al., 2016c; Zhang et al., 2017) . Functional studies have demonstrated that knock-down of FAM83H-AS1 proliferative potential through MET/EGFR signaling in lung adenocarcinoma and NOTCH1 signaling pathway in colorectal cancer. Overexpression of FAM83H-AS1 in luminal type breast cancer associated with good prognosis in patients (Yang et al., 2016a) . Detection of FAM83H-AS1 expression levels in plasma could be a potential diagnostic and prognostic biomarker for breast cancer.
In summary, this study has shed light on novel lncRNA and substantiated several previous findings on lncRNA involved in early stage breast cancers. We report 375 and 94 lncRNA differentially expressed in tumor samples compared to paired and apparent normal samples respectively and 69 DElncRNAs in DCIS compared to apparent normal samples. Seven down regulated and five upregulated lncRNA were further validated to discover significant lncRNA candidate with potential role in breast carcinogenesis. ADAMTS9-AS2 was one of the lncRNA consistently down regulated in patient samples and experimental evidence proved promoter methylation as major cause of ADAMTS9-AS2 down regulation in breast cancer.
Moreover, LINC01614, RP11-490M8.1 and CTB-92J24.3are novel lncRNA reported in our study that has not been associated with breast cancer earlier. Our study also contributes to the existing evidence on MIAT and FAM83H-AS1 as crucial lncRNA expressed at preliminary stages of breast cancer
Data availability
Raw sequencing data is available in Sequence Read Archive hosted by National Center for Biotechnology Information Search database (NCBI) with accession number PRJNA484546. 
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